VEGF immunopositivity related to malignancy degree, proliferative activity and angiogenesis in ENU-induced gliomas.
Growth of solid tumors is highly dependent on angiogenesis. During tumor development, neoplastic cells switch to an angiogenic phenotype, playing a significant role in the expression of the vascular endothelial growth factor (VEGF). Seventy-two brain gliomas were induced in Sprague Dawley rats by prenatal exposure to ethylnitrosourea (ENU). Screening and location of tumors was carried out using magnetic resonance imaging (MRI). Conventional histology and immunocytochemistry for antibodies against glial fibrillary acidic protein (GFAP), S-100, NF, oligodendrocyte Ab-2, Ki-67, and VEGF165 were performed. The proliferation index (PI) was calculated from the Ki-67 labeling index, and the concentration of VEGF165 was quantified by enzyme-linked immunosorbent assay (ELISA). In vivo identification of macro- and microtumor appears to be useful to lead morphological and biochemical studies. Histopathology allows us to identify microtumors as classic oligodendrogliomas (CO; mean PI of 6.01 +/- 2.8%) and macrotumors as anaplastic oligodendrogliomas (AO; mean PI of 14.06 +/- 5%). Classic oligodendrogliomas show scarce VEGF165 expression whereas anaplastic ones display VEGF165 protein level 100-fold increased respect to CO. Astrocytes, neoplastic, and endothelial cells show differential immunostaining patterns from the border to the core of neoplasm. Positive structures for VEGF and their distribution vary according to PI increase. Anaplastic gliomas displaying VEGF-positive intratumor capillaries correspond to the highest PI values. To identify the "angiogenic switch," we propose the glioma stage characterized by VEGF immunopositive neoplastic cells inside the tumor and positive endothelial cells surrounding it.
Bulnes
S
S
Laboratory of Clinical and Experimental Neuroscience (LaNCE), Department of Neuroscience, University of the Basque Country, Leioa, Spain. onbbuses@lg.ehu.es
Lafuente
J V
JV
D000477:Alkylating Agents / Q000494:pharmacology / Q000633:toxicity*; D000818:Animals; D049109:Cell Proliferation; D005038:Ethylnitrosourea / Q000494:pharmacology / Q000633:toxicity*; D005260:Female; D005333:Fetus / Q000187:drug effects; D005910:Glioma / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
D000477:Alkylating Agents; D042461:Vascular Endothelial Growth Factor A; D005038:Ethylnitrosourea